Cellebrite DI Ltd. (CLBT)
Cellebrite DI Ltd. (CLBT) Q4 Earnings Meet Estimates
Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate.
Cellebrite to Report Q4 Earnings: Here's What You Should Know
The surge in subscription filters is likely to have benefited CLBT's top line in the fourth quarter of 2024.
Cellebrite: Country-Wide US Adoption In The Public Sector Is Remarkable
Cellebrite DI LTD (CLBT) offers unique digital investigative solutions to governmental agencies, showing strong market position and 172% stock growth in the past year. CLBT's ambitious financial targets include 24% CAGR in ARR and 20% CAGR in total revenues by 2028, with significant margin improvements since 2022. Despite a potential short-term sell-off, CLBT's low short interest and international customer base, especially in high-growth markets, mitigate long-term risks.
Cellebrite DI: Attractive Company In Connection With AI And Digital Investigation
Cellebrite DI is a top digital forensics play with high barriers to entry, double-digit growth, positive FCF, and a strong balance sheet. The company serves major police forces and Fortune 100 companies, with significant room for growth and high switching costs due to security clearances and data. Cellebrite's competitive edge includes user-friendly digital investigation tools, advanced phone encryption cracking, and AI capabilities, making it essential for law enforcement.
NU or CLBT: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Technology Services sector might want to consider either Nu Holdings Ltd. (NU) or Cellebrite DI Ltd.
Cellebrite DI: Long-Term Growth Looks Positive, But Valuation Increased
I previously rated Cellebrite DI a 'strong buy' due to its growth potential and attractive valuation. Since my recommendation, Cellebrite has outperformed, with the stock rising 160% compared to the S&P 500's 33% increase. Cellebrite has positive developments from its Q3 2024 earnings report.
Cellebrite: There Are Potential Risks That Could Damper Growth
I maintain a neutral rating on Cellebrite due to its premium valuation and risks from CEO transition and potential federal budget cuts. Despite solid growth, including a 27% revenue increase and expanding margins, uncertainties around leadership and federal funding impact my outlook. Strong adoption of Inseyets, Guardian, and Pathfinder products, with notable ARR growth, suggests a long growth runway ahead.
Cellebrite DI Ltd. (CLBT) Q3 2024 Earnings Call Transcript
Cellebrite DI Ltd. (NASDAQ:CLBT ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Andrew Kramer - Investor Relations Yossi Carmil - CEO Dana Gerner - CFO Thomas Hogan - Executive Chairman Conference Call Participants Shaul Eyal - TD Cowen Michael Cikos - Needham Jeffrey Van Rhee - Craig-Hallum Brian Essex - JP Morgan Jonathan Ho - William Blair Tomer Zilberman - Bank of America Max Michaels - Lake Street Capital Operator Welcome to the Cellebrite Third Quarter 2024 Financial Results Conference Call.
Cellebrite DI Ltd. (CLBT) Tops Q3 Earnings and Revenue Estimates
Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share.
What Makes Cellebrite DI Ltd. (CLBT) a New Strong Buy Stock
Cellebrite DI Ltd. (CLBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Cellebrite DI Ltd. (CLBT) Hit a 52 Week High, Can the Run Continue?
Cellebrite DI Ltd. (CLBT) is at a 52-week high, but can investors hope for more gains in the future?
Are Business Services Stocks Lagging Cellebrite DI Ltd. (CLBT) This Year?
Here is how Cellebrite DI Ltd. (CLBT) and Nexxen International Ltd.
